Ji Xunming,MD,PhD
13
2
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
23%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.
Role: lead
The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis.
Role: lead
Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke：Longterm Outcome (OPENS-3L)
Role: lead
Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)
Role: lead
Normobaric Hyperoxia Stabilizing Ischemic Penumbra
Role: lead
Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide
Role: lead
Remote Ischemic Conditioning for the Treatment of Resistant Hypertension
Role: lead
The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke
Role: lead
Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia
Role: lead
Remote Ischemic Conditioning for Motor Recovery After Acute Ischemic Stroke
Role: lead
Study on Prevention and Treatment of Atherosclerotic Cerebral Occlusive Disease With Remote Ischemic Conditioning
Role: lead
Clinical Trial on Remote Ischemic Conditioning and Hypertension（HOPE）
Role: lead
Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)
Role: lead
All 13 trials loaded